Skip to content

CCC Project- Acute Coronary Syndrome

Improving Care for Cardiovascular Disease in China: A Collaborative Project of AHA and CSC (CCC Project) - Acute Coronary Syndrome

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02306616
Enrollment
124363
Registered
2014-12-03
Start date
2014-11-30
Completion date
2020-12-31
Last updated
2021-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Brief summary

To develop and implement quality improvement programs for the treatment of acute coronary syndrome (ACS) in China based on the successful experience of the AHA-Get with the Guidelines program. This program will use data collection, analysis, feedback, and process improvement to extend the use of evidence-based guidelines throughout the healthcare system and improve patient care of acute coronary syndrome.

Interventions

None listed

Sponsors

American Heart Association
CollaboratorOTHER
Chinese Society of Cardiology
CollaboratorOTHER
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Hospitalized patients with discharge diagnosis as acute coronary syndrome (including STEMI, NSTEMI and UAP) in 150 tertiary and 100 secondary hospitals.

Exclusion criteria

None

Design outcomes

Primary

MeasureTime frameDescription
The overall composite of 11 performance measures for ACS careDuration of hospital stay, an expected average of 1 weekPerformance measures for ACS care including: 1. Proportion of patients received aspirin at arrival 2. Proportion of patients received fibrinolytic therapy within 30 mins (STEMI) 3. Proportion of patients received primary percutaneous coronary intervention within 90 mins (STEMI) 4. Proportion of patients received reperfusion therapy (STEMI) 5. Proportion of patients with aspirin prescribed at discharge 6. Proportion of patients with clopidogrel or other P2Y12 inhibitors prescribed at discharge 7. Proportion of patients with beta-blocker prescribed at discharge 8. Proportion of patients with statin prescribed at discharge 9. Proportion of patients received evaluation of left ventricular systolic function 10. Proportion of left ventricular systolic dysfunction patients with ACEI or ARB prescribed at discharge 11. Proportion of patients received smoking cessation advice/ counseling

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 29, 2026